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ABSTRACT Structural changes accompanying the binding of ligands to the cloned human -opioid receptor immobilized in
a solid-supported lipid bilayer have been investigated using coupled plasmon-waveguide resonance spectroscopy. This
highly sensitive technique directly monitors mass density, conformation, and molecular orientation changes occurring in
anisotropic thin films and allows direct determination of binding constants. Although both agonist binding and antagonist
binding to the receptor cause increases in molecular ordering within the proteolipid membrane, only agonist binding induces
an increase in thickness and molecular packing density of the membrane. This is a consequence of mass movements
perpendicular to the plane of the bilayer occurring within the lipid and receptor components. These results are consistent with
models of receptor function that involve changes in the orientation of transmembrane helices.
INTRODUCTION
The majority of transmembrane signal transduction re-
sponses to hormones, neurotransmitters, phospholipids,
photons, odorants, and growth factors are mediated by a
superfamily (containing nearly 2000 members and growing)
of seven transmembrane helical G-protein-coupled recep-
tors (GPCRs). Activation of these receptors by external
stimuli is assumed to require protein conformational
changes. Current methods used to examine ligand-binding
interactions with such GPCRs, as well as with other mem-
brane-bound receptors, suffer from several deficiencies.
These include the use of radiolabeled ligands, which require
special synthetic methodologies, and present special dis-
posal and potential toxicity problems. In some cases, li-
gands with fluorescent probes can be used, but the modifi-
cation of the ligand by the fluorophore often leads to
changes in the binding and other physical/chemical proper-
ties of the ligand. Perhaps most importantly, current binding
methods, whether using radiolabeled or fluorescent-labeled
ligands, provide no information regarding the changes in
receptor structure that accompany ligand-receptor interac-
tions, nor do they distinguish the different structural
changes that occur for agonists and antagonists interacting
with the same receptor.
We report herein results obtained with a new method
employing plasmon resonance spectroscopy that can mon-
itor the binding interaction of peptide ligands with a GPCR.
The information thereby obtained includes the direct deter-
mination of the thermodynamic binding constant for the
noncovalent ligand-receptor interaction and an assessment
of the structural changes that accompany this interaction, all
in a single, highly sensitive measurement using unmodified
materials. The procedure utilizes a newly developed variant
of the surface plasmon resonance (SPR) technique referred
to as coupled plasmon-waveguide resonance (CPWR) spec-
troscopy (Salamon et al., 1997a, 1999; Salamon and Tollin,
1999a, 2000), which allows the characterization of aniso-
tropic membrane systems (Salamon et al., 1997a, 1998,
1999), as well as other anisotropic nanostructures (Salamon
and Tollin, 1999b, 2000). This methodology has the unique
capability of independently examining real-time changes in
the structure of the receptor both parallel and perpendicular
to the lipid membrane plane in response to receptor-ligand
interactions (Salamon et al., 1999). CPWR also provides
greatly enhanced sensitivity and spectral resolution com-
pared to conventional SPR. As will be demonstrated below,
only femtomole amounts of receptor (and ligand) are
needed for complete spectral determination and analysis.
Furthermore, because radioactivity measurements do not
have to be performed, the methodology is much more rapid
and direct in the determination of critical binding parame-
ters. CPWR spectroscopy thus provides a general procedure
that we believe can replace previous methods for examining
ligand-membrane-bound receptor interactions, and which at
the same time can provide new information about ligand-
receptor structural transitions that are not available with
these methodologies.
In the present report, we illustrate this procedure via
incorporation of the human -opioid receptor into a pre-
formed lipid bilayer, examination of the binding to the
receptor of the highly selective ligand DPDPE (c-[D-Pen2,
D-Pen5] enkephalin; Mosberg et al., 1983), demonstration of
the reversal of binding using the selective antagonist nal-
trindol (NTI; Raynor et al., 1994; Korlipara et al., 1995),
and evaluation of the changes in the receptor structure that
accompany these binding interactions. We present clear
evidence that significantly different structural changes are
induced in the -opioid receptor upon binding of either
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DPDPE or NTI, thereby providing new insights into the
structural basis of receptor function.
EXPERIMENTAL PROCEDURES
Purification of the receptor
The human brain -opioid receptor (accession number U07882; Knapp et
al., 1994) mediates analgesic responses to endogenous enkephalins as well
as to a variety of synthetic agonists. A fully functional receptor, labeled at
the C terminus with a myc epitope (Gimpl et al., 1996) and His tag
(Grisshammer and Tucker, 1996), was prepared by inserting the DNA of
the human -opioid receptor, which was modified by incapacitating the
stop codon of the receptor, into the pcDNA3 vector containing the myc/His
tag (Invitrogen). The entire vector was verified by DNA sequencing and
stably transfected into a Chinese hamster ovary cell line with the use of
diethylaminoethyl-dextran (Promega). The transfected clones were se-
lected using G418 as an antibiotic. These were grown to confluency in
Hamm’s F12 medium with 10% fetal bovine serum containing penicillin
(100 units/ml) and streptomycin (100 g/ml) in a humidified CO2 atmo-
sphere at 37°C. Related experiments characterizing the modified receptor
have been carried out (Okura et al., 2000).
After the cells were harvested and washed several times, they were
suspended in Tris-Cl buffer at pH 7.4 and centrifuged at 42,000 rpm
(160,000  g) at 4°C for 30 min. The buffer was decanted and the
membranes were solubilized by homogenization in a solution containing
25 mM HEPES, 0.5 M KCl, 30 mM octylglucoside, and protease inhibitors
designed to be used with metal chelating columns (Sigma) (buffered at pH
7.4). After homogenization the solution was centrifuged at 42,000 rpm
again for 60 min to remove cell debris.
The receptor was purified on a Talon Co2 metal chelating column
(Clontech) with gentle rocking for 48 h at 12°C and eluted with 25 mM
HEPES, 0.5 M KCl, 30 mM octylglucoside, and 100 mM imidazole
buffered at pH 7.4. Although the binding can be carried out in 24 h, this
experiment was allowed to go for 48 h to maximize binding of the receptor
to the Talon column. The column and receptor homogenate were kept at
12°C to minimize any possible denaturation of the receptor due to heat or
protease, which may still be present in the system. The concentration of
receptor in the purified sample was determined in a binding assay using a
radioactive ligand (Okura et al., 2000).
The agonist (DPDPE) used in this work was synthesized in Dr. Victor
Hruby’s laboratory (Mosberg et al., 1983), and the antagonist (NTI) was
obtained from RBI Labs.
Formation of solid-supported lipid bilayers
Self-assembled solid-supported lipid membranes were prepared according
to the method used for the formation of freely suspended lipid bilayers
(Mueller et al., 1962). This involves spreading a small amount of lipid
solution across an orifice in a Teflon sheet that separates the thin dielectric
film (SiO2) from the aqueous phase (Salamon et al., 1999). The hydrophilic
surface of hydrated SiO2 attracts the polar groups of the lipid molecules,
thus inducing an initial orientation of the lipid molecules, with the hydro-
carbon chains pointing toward the droplet of excess lipid solution. The next
steps of bilayer formation, induced by adding aqueous buffer to the sample
compartment of the CPWR cell, involve a thinning process and the for-
mation of a plateau-Gibbs border of lipid solution that anchors the mem-
brane to the Teflon spacer. In the present experiments, the lipid films were
formed from a solution containing 5 mg/ml egg phosphatidylcholine (PC)
and 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)(sodium
salt) (POPG) (75:25 mol/mol) in squalene/butanol/methanol (0.05:9.5:0.5,
v/v). The lipids were purchased from Avanti Polar Lipids (Birmingham,
AL). All experiments were carried out at ambient temperature, using
10 mM Tris buffer containing 0.5 mM EDTA and 10 mM KCl (pH 7.3),
in the 2-ml sample cell.
CPWR spectroscopy
Details of the procedures for CPWR measurement and data analysis have
been described elsewhere (Salamon et al., 1997a, 1999; Salamon and
Tollin, 1999a). The method is based upon the resonant excitation by
polarized light from a CW He-Ne laser (  632.8 nm), passing through
a glass prism under total internal reflection conditions, of collective elec-
tronic oscillations (plasmons) in a thin metal film (Ag) deposited on the
external surface of the prism, which is overcoated with a dielectric layer
(SiO2). The resonant excitation of plasmons generates an evanescent elec-
tromagnetic field localized at the outer surface of the dielectric film, which
can be used to probe the optical properties of molecules immobilized on
this surface (for details see Salamon et al., 1997a, 1999; Salamon and
Tollin, 1999a, 2000). Resonance is achieved either by varying the incident-
light wavelength () at a fixed incident angle (), or by varying  at a fixed
 (in the present experiments the latter protocol was used). Because the
resonance coupling generates electromagnetic waves at the expense of
incident light energy, the intensity of totally reflected light is diminished.
The reflected light intensity as a function of either  or  results in a
CPWR resonance spectrum. The resonance can be excited with light
polarized either parallel (p) or perpendicular (s) to the incident plane,
resulting in two well-separated spectra (Salamon et al., 1997a), thereby
allowing characterization of the molecular organization of anisotropic
systems such as biomembranes containing integral proteins (Salamon et al.,
1994, 1996, 1998, 1999). Under the experimental conditions employed in
this work the optical parameters obtained with p-polarization refer to the
perpendicular direction, and those obtained with s-polarization to the
parallel direction, relative to the bilayer membrane surface.
CPWR spectra can be described by three parameters:  (or ), the
spectral width, and the resonance depth. These depend on the refractive
index (n), the extinction coefficient (k), and the thickness (t) of the
plasmon-generating and emerging media, the latter including a thin film
deposited on the silica surface (i.e., a proteolipid membrane in the present
case) in contact with an aqueous solution. Thin-film electromagnetic theory
based on Maxwell’s equations provides an analytical relationship between
the spectral parameters and the optical properties of these media. This
allows evaluation of n, k, and t uniquely for the three media (i.e., the
plasmon-generating medium, the proteolipid membrane, and the aqueous
buffer solution), by nonlinear least-squares fitting of the theoretical spec-
trum to the experimental one (for details see Salamon et al., 1997b, 1998,
1999, 2000; Salamon and Tollin, 1999b). Inasmuch as the excitation
wavelength (632.8 nm) is far removed from the absorption bands of the
lipids, protein, and ligands used in this work, a k value other than zero
reflects a decrease in reflected light intensity due only to scattering result-
ing from imperfections in the proteolipid film. This effect will not be
discussed further in the present work.
It is important to point out that for an anisotropic thin film, such as the
proteolipid membrane in the present work, the thickness (t) represents an
average molecular length perpendicular to the plane of the film and will be
independent of light polarization. In contrast, the values of the refractive
index (n) will be very much dependent on the polarization of the excitation
light. Furthermore, for uniaxial anisotropic structures in which the optical
axis is parallel to the p-polarization direction, the np value will always be
larger than ns. This is a consequence of the fact that the measured refractive
index of a material is determined by the polarizability of the individual
molecules. The latter property describes the ability of a molecule to interact
with an external electromagnetic field and in general is anisotropic with
respect to the molecular frame. In the simplified case in which the molec-
ular shape is rod-like (e.g., the phospholipid molecules used in this work),
one can assign two different values to the polarizability: the larger one,
which is longitudinal, and the smaller one, which is transverse. If, in
addition to the anisotropy in molecular shape and polarizability, the system
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that contains these molecules is ordered such that the long axes of the
molecules are parallel, this results in long-range order usually described by
the order parameter S. In this situation the values of the polarizability,
averaged over the whole system and measured either parallel or perpen-
dicular to the direction of the long axes of the molecules, will be different
(i.e., the parallel value will be larger than the perpendicular one). These
conditions create an optically anisotropic system, with the optical axis
perpendicular to the plane of the proteolipid membrane, and the values of
the refractive index measured with two polarizations of light (i.e., parallel,
np, and perpendicular, ns, to the optical axis) will describe this optical
anisotropy (An) as follows:
An np
2 ns
2/nav
2  2 (1)
In this equation nav is the average value of the refractive index and, for a
uniaxial system, is given by
nav
2  1/3np
2 2ns
2 (2)
In summary, the anisotropy in the refractive index reflects both the
anisotropy in the molecular polarizability and the degree of long-range
order of molecules within the system and therefore can be used as a tool to
analyze structural organization (i.e., molecular orientation). This is partic-
ularly important in the context of the present work, in which structural
alterations of a proteolipid membrane (consisting of a single lipid bilayer
with inserted receptor molecules) caused by ligand binding have been
monitored by changes in the refractive index anisotropy. A more quanti-
tative discussion of this will be presented separately (Salamon and Tollin,
manuscript in preparation).
Furthermore, as can be seen from the Lorentz-Lorenz relation, the
average value of the refractive index is also directly related to the mass
density (for details see Born and Wolf, 1965; Cuypers et al., 1983). Thus,
from the thickness of the proteolipid film and the average value of the
refractive index one can calculate the surface mass density (or molecular
packing density), i.e., mass per unit surface area (or number of moles per
unit surface area; Salamon et al., 1999; Salamon and Tollin, 1999a, 2000).
In the present experiments, the plasmon-generating device was cali-
brated by measuring the CPWR spectra obtained from a bare silica surface
in contact with aqueous buffer with both p- and s-polarized light and then
fitting these with theoretical curves. The goal of such a calibration is to
obtain the optical parameters of the silica layer (i.e., refractive indices,
extinction coefficients, and thickness) used in these experiments. This
provides an input set of data used in analyzing the resonance spectra
obtained with proteolipid membranes deposited on the silica surface. Thus
the resonance spectra obtained after a single lipid bilayer membrane was
created on the hydrophilic surface of silica were fit using these data,
yielding the optical parameters (np, ns, and t) for the lipid bilayer. These
allowed the calculation of the refractive index anisotropy and the surface
mass density (i.e., molecular packing density) of the bilayer. After incor-
poration of the receptor molecules into the lipid membrane, the resulting
CPWR spectra allowed us to characterize the structural consequences of
receptor incorporation. Finally, addition to the aqueous sample compart-
ment of the CPWR cell of either agonist or antagonist again resulted in
changes of the CPWR spectra, which reflected structural alterations in the
proteolipid membrane caused by the receptor-ligand interaction.
RESULTS AND DISCUSSION
Incorporation of the -opioid receptor into a
preformed lipid bilayer
Receptor molecules were incorporated into a preformed
lipid membrane deposited on the hydrophilic surface of the
silica film by adding small aliquots of a concentrated solu-
tion of the human -opioid receptor solubilized in 30 mM
octylglucoside to the aqueous compartment of the CPWR
cell, thereby diluting the detergent to a final concentration
below its critical micelle concentration (25 mM) (Salamon
et al., 1994, 1996). This resulted in spontaneous transfer of
the receptor from the micelle to the lipid bilayer. The
direction of insertion of the receptor in the bilayer is not
known. However, as will be shown below, ligand binding to
the incorporated receptor occurs efficiently.
Fig. 1 shows typical CPWR spectra, obtained with either
p-polarized (Fig. 1 A) or s-polarized (Fig. 1 B) exciting
light, for a solid-supported lipid membrane before (curve 1)
FIGURE 1 CPWR spectra obtained for a supported lipid bilayer con-
taining 75 mol% egg phosphatidylcholine and 25 mol% phosphatidylglyc-
erol before (curve 1) and after the addition of aliquots of human -opioid
receptor in octylglucoside-containing buffer to the aqueous compartment
of the CPWR cell (the final receptor concentration in the bulk solution for
curve 2 was 4.8 nM, and that for curve 3 was 12.8 nM). The buffer
composition was 10 mM Tris (pH 7.3), 0.5 mM EDTA, and 10 mM KCl.
The octylglucoside concentration in the receptor solution was 30 mM; after
dilution into the sample cell the concentration ranged from 0 to 5 mM. Data
obtained with p-polarized (A) and s-polarized (B) exciting light are shown.
Dotted lines represent theoretical fits. The refractive index and thickness
values obtained from these fits are given in Fig. 4. In all cases, CPWR
spectra were obtained after equilibrium was reached (20–40 min).
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and after two additions of detergent-solubilized receptor to
the aqueous compartment of the sample cell (curves 2 and
3). As noted previously with other integral membrane pro-
teins, including rhodopsin (Salamon et al., 1994, 1996),
protein incorporation into the bilayer influences all three
parameters of the resonance spectrum, i.e., angular position,
depth, and spectral half-width. Such changes are due both to
mass density changes and to structural alterations of the
proteolipid membrane (reflected in changes in refractive
index and thickness). These will be considered further be-
low.
Binding of agonist (DPDPE) and antagonist (NTI)
to incorporated receptor
In this section we describe the primary spectral data ob-
tained upon adding DPDPE and NTI to the previously
incorporated receptor. As will be demonstrated, these data
clearly reveal different patterns of receptor-agonist and re-
ceptor-antagonist interaction.
When aliquots of either DPDPE or NTI solutions are
added to the sample cell after receptor incorporation into a
preformed bilayer, significant changes in the position,
width, and depth of the CPWR resonance curve occur.
These spectral changes reflect the binding of these mole-
cules to the proteolipid membrane. Control experiments
involving the addition of comparable amounts of these
ligands to a CPWR cell containing a preformed bilayer in
the absence of receptor produced no measurable effects on
the CPWR spectra (data not shown), indicating that non-
specific binding to the membrane is not detected in these
experiments. Thus the spectral changes observed when the
receptor is present must reflect receptor-ligand interactions.
To illustrate these changes, examples of resonance spec-
tra obtained with both p- and s-polarized exciting light are
shown in Figs. 2 and 3. Fig. 2 shows the results of an
experiment in which agonist is added to the receptor-con-
taining CPWR cell first, followed by antagonist addition,
and Fig. 3 shows an experiment in which antagonist is
added first, followed by agonist. As can clearly be seen, the
effects of these two ligands on the resonance spectra are
easily measurable and quite different. Although all three
spectral parameters (i.e., position, width, and depth) are
significantly altered by both ligands, appreciable differ-
ences are seen in the amplitude and direction of the reso-
nance shifts. Thus DPDPE causes much larger changes in
FIGURE 2 CPWR spectra obtained in an experiment in
which addition to the aqueous compartment of agonist
(DPDPE) is followed by the addition of antagonist (NTI).
The cell contained a lipid membrane with the receptor
incorporated (the final bulk receptor concentration was
12.8 nM; spectra are shown in curves 1 in A and B).
Curves 2 in A and B show the spectra obtained after the
addition of 79 nM DPDPE. Curves 1 in C and D are the
same as curves 2 in A and B. Curves 2 in C and D show
the spectra obtained after the addition of 0.64 nM NTI.
Other conditions are as in Fig. 1.
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both p- and s-polarized spectra (compare Fig. 2, A and B,
with Fig. 3, A and B) than are induced by NTI. In addition,
DPDPE shifts both resonances to larger incident angle val-
ues (see Fig. 2, A and B, and Fig. 3, C and D), although the
change in the p-polarized signal is quite small (see Fig. 5).
In contrast, NTI moves the p-polarized resonance to larger
(see Figs. 2 C and 3 A) and the s-polarized resonance to
smaller, incident angles (see Figs. 2 D and 3 B).
To further illustrate these differences, plots of the reso-
nance position shifts as a function of added concentration of
the two ligands are shown in Figs. 4 and 5. These data also
illustrate the fact that adding antagonist after agonist does
not simply reverse the changes generated by agonist binding
(see Fig. 4). In contrast, agonist added after antagonist is
bound is able to reverse the changes caused by the receptor-
antagonist interaction (as can clearly be seen in the s-
polarized component in Fig. 5).
It is essential to emphasize that these spectral changes
saturate within concentration ranges (0–40 nM for DPDPE
(see Fig. 4) and 0–0.1 nM for NTI (see Fig. 5)) that are
consistent with literature data for the binding characteristics
of the ligands (see discussion below). Thus it is very un-
likely that such high binding affinities result from nonspe-
cific receptor-ligand interactions. Furthermore, the results
presented in Figs. 4 and 5 also clearly indicate that, although
the direction of the shifts remains the same regardless of
which ligand is added first, the concentration ranges in
which the resonance shifts occur depend on the sequence of
addition (compare Figs. 4 and 5). Thus, in the experiments
in which agonist is added first, the antagonist concentration
range is significantly higher than that for the opposite case.
The same observation applies to the agonist when the an-
tagonist is added first. We will return to this point below.
Preliminary time-resolved measurements of the CPWR
spectra after ligand addition demonstrate quite different
kinetic properties, depending on which ligand is interacting
with the receptor. Fig. 6 shows an example of such a
time-dependent spectral sequence obtained with DPDPE,
using s-polarized light. There are two significant features of
these spectral changes that distinguish the receptor-agonist
interaction from that of the receptor-antagonist interaction.
First, agonist addition results in a very slow (on the order of
minutes) time course of spectral changes, whereas antago-
nist addition results in spectral changes that occur faster
than the resolution time (10 s) of the present experiments.
Second, the kinetic properties of the spectral alterations
FIGURE 3 CPWR spectra obtained in an experiment in
which the addition of antagonist is followed by the addition
of agonist. The cell contained a lipid membrane containing
the receptor, as in Fig. 2 (the final bulk concentration was
12.8 nM; the spectra are shown in curves 1, A and B).
Curves 2 in A and B show the spectra obtained after the
addition of 0.144 nM NTI. This was followed by the
addition of 360 nM DPDPE (curve 2, C and D). Curve 1 in
C and D is the same as curve 2 in A and B. Other conditions
are as in Fig. 1.
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observed with the agonist are quite complicated, involving
negative shifts followed by positive shifts in an overall
multiphasic process (which we have not characterized in
full detail). Such results indicate a complex process of
receptor-ligand interaction. It is important to note that a
similar complex pattern of spectral changes is observed with
the p-polarized component (data not shown).
The above-noted differences between agonist and antag-
onist binding properties cannot be explained simply by
differences in either the adsorbed mass of the ligand or its
rate of diffusion to the receptor, inasmuch as these ligands
have similar molecular masses (i.e., 648 for DPDPE and
414 for NTI). Furthermore, preliminary experiments using
another highly selective -opioid agonist, deltorphin II
(Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2; data not shown), re-
veal a kinetic pattern similar to that observed with DPDPE.
It is also important to note that the present data for the
-opioid receptor show striking parallels to recent studies
with the 	2 adrenergic receptor, in which fluorescence spec-
troscopy was used to delineate structural changes associated
with receptor-ligand interaction (Gether et al., 1997). In
these experiments the time course of fluorescence clearly
demonstrated that the kinetics of the receptor-agonist inter-
action are very comparable to those observed in the present
study (Fig. 6, inset), showing slow (on the order of minutes)
multiphasic kinetics, whereas the receptor-antagonist inter-
action is much faster and simpler.
Although it is clear that further time-resolved studies are
necessary to fully understand the complexity of the recep-
tor-agonist interaction process (such studies are presently
under way), it is possible to conclude from the present data
that the interaction of the -opioid receptor with agonist or
antagonist generates different structural states of the prote-
olipid membrane, the properties of which depend on the
sequence of ligand addition. To provide a quantitative de-
scription of such states it is necessary to analyze the spectral
FIGURE 4 Dependence of the relative position of
the CPWR resonance minimum on the agonist (DP-
DPE) and antagonist (NTI) concentrations in the sam-
ple compartment of the cell, obtained using either p-
(F) or s- (Œ) polarization. Resonance position dis-
placement toward higher values represents shifts to
larger angles of incidence. Results were obtained in a
continuation of the experiment described in Fig. 2.
After receptor incorporation, aliquots of the agonist
solution in buffer were added; this was followed by the
addition of aliquots of the antagonist solution. Other
conditions are as in Fig. 1.
FIGURE 5 Dependence of the relative position of
the CPWR resonance minimum on the antagonist
(NTI) and agonist (DPDPE) concentration in the sam-
ple compartment of the cell, obtained using either p-
(F) or s- (Œ) polarization. Resonance position dis-
placement toward higher values represents shifts to
larger angles of incidence. Results were obtained in a
continuation of the experiment described in Fig. 3.
After receptor incorporation, aliquots of antagonist so-
lution in buffer were added; this was followed by the
addition of agonist solution. Conditions are as in Fig. 1.
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changes in more detail, taking into account alterations of all
three spectral parameters (i.e., resonance position, depth,
and width). Such an analysis (see next section) yields the
optical parameters of the system, which can be used in a
quantitative characterization of the receptor-ligand binding
processes.
Structural consequences of receptor
incorporation and ligand binding
Characterization of the receptor-containing lipid membrane
Quantitative analysis of the plasmon resonance spectra ob-
tained during receptor incorporation can be accomplished
by fitting theoretical curves to the experimental spectra (see
Fig. 1). Fig. 7 shows plots of the optical parameters obtained
from such a procedure (n (Fig. 7 A) and t and An (Fig. 7 B);
see Experimental Procedures for parameter definitions) as a
function of added receptor. The solid lines are single hy-
perbolic curves fitted to the data points. These results indi-
cate the following: 1) The process of receptor incorporation
is satisfactorily fit by a simple Langmuir isotherm. 2) The
low value of the apparent insertion constant (14 nM)
argues for a quite high efficiency of incorporation. 3) The
extrapolated thickness value (6.8 nm) describes the dimen-
sion of the incorporated protein molecule perpendicular to
the membrane plane (i.e., the distance between the external
loops plus bound water on both sides of the membrane).
Extrapolation of the refractive index curves to infinite re-
ceptor concentration (Fig. 7 A) results in values (np	 and
ns	) that characterize a monolayer of densely packed re-
ceptor molecules. From these one can calculate an average
value of the refractive index (from Eq. 2) and then mass
density or surface concentration (Salamon et al., 1999).
From the latter value and the molecular mass of the receptor
(using a molecular mass of 60 kDa), the surface area occu-
pied by one receptor molecule can be evaluated as Srec 
1200
 100 Å2. It is important to note that this value for the
opioid receptor is in very good agreement with reported
values for rhodopsin obtained with several techniques: SPR
(1260 Å2; Salamon et al., 1996), electron cryomicroscopy
(1000 Å2; Schertler et al., 1993; Unger and Schertler,
1995), and a rhodopsin Langmuir-Blodgett film with x-ray
scattering (1100 Å2; Maxia et al., 1995). 4) The increase
in the proteolipid membrane anisotropy occurring during
the process of receptor incorporation (shown in Fig. 7 B)
clearly reflects a corresponding increase of the average
long-range molecular order in the membrane resulting from
receptor-lipid interactions.
Characterization of the receptor-ligand interactions
In general, CPWR spectral changes obtained with an opti-
cally anisotropic thin proteolipid membrane (i.e., changes in
position, depth, and width) are the result of both mass
density (molecular packing density) and structural alter-
ations occurring within the system (for details see Salamon
et al., 1999; Salamon and Tollin, 1999a,b). The mass den-
sity changes are directly reflected by the average value of
the refractive index changes (see Eq. 2), whereas structural
alterations will influence the refractive index anisotropy
because of changes in the orientational order of molecules
within the membrane. The latter quantity can be measured
by changes in the refractive index values obtained with p-
and s-polarized light (see Eq. 1 and further discussion
below). Distinguishing between these two types of changes
is especially important in the case of receptors, in which the
receptor-ligand interactions are thought to result in struc-
tural alterations. This distinction can be accomplished by
FIGURE 6 CPWR time-resolved spectra obtained
with s-polarized light, using a lipid membrane contain-
ing receptor (final bulk concentration 12.8 nM) as
described in Fig. 1 (curve 1). Curves 2 and 3 were
obtained 20 s and 60 s after the addition of 7 nM
agonist to the CPWR sample cell, respectively. (Inset)
Resonance position shift as a function of time after the
addition of agonist.
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fitting theoretical resonance curves to the experimental
CPWR spectra. Using the structural parameters obtained for
the receptor-containing proteolipid membrane (described in
the preceding section), we have fitted theoretical resonance
spectra to the experimental curves obtained in both agonist-
antagonist and antagonist-agonist experiments (see Figs.
2–5). The results, expressed as changes in refractive index
anisotropy, An, and proteolipid membrane thickness, as a
function of added ligand are shown in Figs. 8 and 9,
respectively.
As noted above, binding of the two ligands drives the
proteolipid membrane system into distinct states character-
ized by different spectral characteristics (see Figs. 2–6).
Based on the results in Figs. 8 and 9, one can conclude that
agonist binding (either before or after antagonist binding)
causes conformational changes in the receptor molecule that
result in net increases in both anisotropy and mass density
of the proteolipid system. The contribution of the ligand
itself to these changes must be relatively small because of
its small size and mass compared to the receptor and sur-
rounding lipid molecules. Mass density increases are shown
by the increased values of both nav (see inset in Fig. 8) and
t (preliminary experiments using another -opioid receptor
agonist, deltorphin II, showed very similar changes in mass
density, An, and t upon binding to the receptor; data not
shown). In contrast, antagonist binding to the receptor in-
duces only anisotropy changes in the system (i.e., there are
no measurable changes in either nav or t values). These
conclusions are consistent with the data given in Figs. 2–5
and are especially well illustrated by the resonance position
shifts shown in Fig. 4, in which the agonist induces unidi-
rectional (i.e., p- and s-components shift in the same direc-
tion), whereas the antagonist induces bidirectional reso-
nance position shifts. Unidirectional shifts of both spectral
components in the agonist case is clear evidence of an
increase in both np and ns values (i.e., an increase in the
average refractive index value; see Eq. 2), which occurs as
a result of a mass density increase. In contrast, the addition
of antagonist either before (Fig. 5) or after (Fig. 4) agonist
addition does not result in mass density changes. In the
latter case, all of the spectral changes are related to struc-
tural alterations. Because the two ligands have comparable
molecular masses, these results must be a consequence of
the addition of lipid mass to the bilayer caused by the
structural changes of the receptor upon interaction with the
agonist (for further discussion see below).
It is also important to note that the conformational state of
the receptor induced by the antagonist has a much higher
refractive index anisotropy than that produced by the ago-
nist. This is clearly shown in both types of experiment (see
Figs. 8 and 9). Thus, when the agonist is added before the
antagonist, the latter ligand increases the anisotropy to al-
most double the value produced by the agonist. In contrast,
when the agonist is added after the antagonist, the value of
An is decreased to a level comparable to the increase pro-
duced by the agonist alone. In general, changes in refractive
index anisotropy are produced by alterations in the molec-
ular ordering with respect to the bilayer normal. In the
present system, this must be a consequence of conforma-
tional changes in the receptor molecules accompanying
ligand binding, i.e., changes in position and orientation of
the transmembrane helices involving tilting and rotational
movements, as well as movements occurring in the ex-
tramembrane loops. Changes in the acyl chain ordering of
the lipid molecules induced by these protein structural al-
terations may also contribute.
In summary, the lack of measurable alterations in mass
density or membrane thickness upon antagonist binding
FIGURE 7 Refractive index (A) and thickness (B; Œ) values of the
proteolipid film as a function of the receptor concentration, obtained from
theoretical fits as described in Fig. 1. Data in A were obtained using either
p- (F) or s- (Œ) polarized light (error bars due to uncertainties in curve
fitting lie within symbols). B also shows the refractive index anisotropy
(An; F) as a function of the receptor concentration. Solid lines in both
panels represent nonlinear least-squares fits to a hyperbolic function. These
yield limiting values of both n (given in figure) and t (6.8 nm) extrapolated
to infinite concentration of the receptor, as well as an apparent binding
constant KD (given in figure).
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implies a critical difference in the conformational changes
induced by such binding compared with those induced by
the agonist. This distinction is also reflected in the fact that
the state of the proteolipid membrane created by the addi-
tion of antagonist before agonist is different from that
created when antagonist is added after agonist. These dif-
ferences arise because the agonist is able to generate struc-
tural alterations perpendicular to the plane of the membrane,
changing its thickness, whereas the antagonist cannot do so.
Thus the antagonist produces two substates, depending
upon whether it is interacting with the unliganded receptor
or with a receptor that has agonist bound to it and therefore
has changed its dimensions relative to the membrane nor-
mal. Although these two substates are characterized by
similar optical anisotropies, they have different dimensions
and mass density. Because NTI is a pure  receptor antag-
onist with no reported partial agonist biological activities
(Wild et al., 1994), it is reasonable to conclude that both of
these substates are inactive in signal transduction. While it
is possible that the short-lived state represents the receptor
state that could lead to negative intrinsic activity (Costa et
al., 1992) if it were long lived enough, a more likely
possibility is that the two substates represent nonequilib-
rium steady states (Kenakin, 1990) that are accessible to the
receptor, with one of these being only transiently observed
when NTI interacts with the  receptor. To obtain further
insights into these states, structural changes in the lipid and
protein components must be separately determined for both
agonist and antagonist binding and under a wide range of
ratios of agonist to antagonist. This can be done using
chromophore-labeled lipids, and such experiments are un-
der way.
Thermodynamic values for the individual ligand dissoci-
ation constants can easily be evaluated from the hyperbolic
fits to the anisotropy changes presented in Figs. 8 and 9. The
results are given in Table 1. It is evident that these disso-
FIGURE 8 Average change in thickness (F)
and refractive index anisotropy values (Œ) for a
proteolipid membrane containing opioid receptor
(bulk concentration 12.8 nM) as a function of the
agonist and antagonist concentration. Results
were obtained from the experiment in Fig. 4 by
theoretical fits to the experimental spectra (see
Figs. 1 and 7). (Inset) Square of the average
refractive index of the proteolipid membrane as a
function of agonist concentration. Solid lines rep-
resent nonlinear least-squares fits to a hyperbolic
function from which the binding constant values
(KD) were obtained. For purposes of clarity, error
bars (corresponding to curve fitting errors) for
circles and triangles are shown only for one of the
two curves in the main panel.
FIGURE 9 Average change in thickness (F)
and refractive index anisotropy values (Œ) as a
function of antagonist and agonist concentration.
Results were obtained from the experiment in Fig.
5 by theoretical fits to the experimental spectra.
Other details are as in Fig. 8.
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ciation constants strongly depend on whether the agonist is
present when the antagonist is added, and vice versa. Thus
the presence of the other ligand causes an appreciable shift
of KD to higher values. This observation is especially sig-
nificant in the present system, in which the antagonist has a
much higher binding affinity than the agonist (by two to
three orders of magnitude). Despite this, when NTI is added
after DPDPE, its dissociation constant increases signifi-
cantly (about fourfold). This finding cannot be simply ex-
plained by competition between these two ligands. We
conclude that this constitutes another indication that differ-
ent conformational states are induced by these ligands,
which are characterized by different binding constants for
the other ligand.
The binding constants determined here for DPDPE and
NTI are similar to those reported in the literature, using a
variety of -opioid receptor membrane preparations and a
variety of radiolabeled competitive ligands. For DPDPE,
some typical values reported in the literature include 3.3–
5.2 nM in several rat brain membrane preparations
(Akiyama et al., 1985), 1.2 nM for the receptor cloned into
the NG-108-15 cell line (Akiyama et al., 1985), and 85 nM
for the receptor cloned into the Chinese hamster ovary cell
line (unpublished data). Thus the KD values of 10–40 nm
reported here are consistent with those expected for a fully
functional receptor. Likewise, the KD values previously
reported (Wild et al., 1994) for NTI (0.9 nM in NG-108-15
cloned receptors, 0.13 nM in mouse brain membranes, and
0.15 nM in mouse spinal chord preparations) are consistent
with the values of 0.02–0.10 nM reported here.
Structural basis of receptor function
The CPWR results presented in this paper demonstrate the
formation of several conformational states of the proteolipid
membrane as a consequence of receptor-agonist and recep-
tor-antagonist interactions. In the case of agonist binding,
the slow multiphasic kinetics clearly indicate that there are
a number of intermediate conformational states involved in
the formation of the final activated state, as has been sug-
gested by Gether and Kobilka (1998). It is not clear at
present whether this final state involves an equilibrium
mixture of different conformational forms of the receptor, or
preferential formation of one particular receptor structure
(Kenakin, 1995). In either case, the present study has shown
that the receptor-agonist conformation produces an elonga-
tion of the receptor molecule (an increase in t), as well as an
overall increase in the degree of orientational order of
molecules within the membrane (an increase in refractive
index anisotropy, An). It is reasonable to expect this process
to be relatively slow because it also involves alterations in
the lipid phase of the membrane in response to receptor
elongation. Based on models for opioid receptor structural
changes upon activation (Pogozheva et al., 1998; Knapp et
al., 1995; Gether and Kobilka, 1998), derived from studies
of rhodopsin (Farrens et al., 1996), bacteriorhodopsin (Lu-
ecke et al., 1999), and the 	-adrenergic receptor (Gether and
Kobilka, 1998), we suggest that the elongation process
involves tilting and rotation of one or more of the trans-
membrane helices, resulting in vertical movements of the
extramembrane loops, and is accompanied by movement of
lipid molecules that cause an increase in the positive cur-
vature of the lipid surface. The increase in curvature also
requires the movement of lipid molecules from the plateau-
Gibbs border to the bilayer phase, which increases the
overall surface mass density of the proteolipid membrane.
The anisotropy changes can be ascribed predominantly to
orientation changes of the transmembrane helices that in-
fluence the ordering of the hydrocarbon chains of lipid
molecules, without a significant contribution from the ex-
tracellular loops or lipid mass redistribution. In contrast, the
binding of antagonist results only in an increase in the
refractive index anisotropy, which implies localized alter-
ations occurring within the receptor molecule that are re-
stricted to transmembrane helix and lipid hydrocarbon chain
orientation. The schematic model shown in Fig. 10 repre-
sents an attempt to visualize the structural consequences of
-opioid receptor interaction with either agonist or antago-
nist based on these observations. Such a multistate model
allows a simple explanation of the well-known fact that
competitive antagonists, although they occupy the same
binding site in the receptor as agonists, do not transduce
signals across the proteolipid membrane.
A more complete understanding of the molecular mech-
anisms of receptor-ligand interactions will require more
detailed information about the structural changes induced in
the receptor by different classes of ligands. In particular,
further time-resolved studies are needed to characterize the
sequence of conformational changes associated with the
intermediate states that follow ligand binding. It will also be
important to increase our knowledge of the effects of lipid
membrane structure, salt concentration, pH, other ligands
such as allosteric effectors, and other proteins (e.g.,
G-proteins, kinases, etc.) on the formation of the liganded
states of the receptor. The present studies have shown that
CPWR spectroscopy provides a new and powerful experi-
mental tool for such investigations, for GPCRs as well as
other membrane-bound receptors, enzymes, ion channels,
TABLE 1 Dissociation constant values obtained for DPDPE
and NTI from experiments described in Figs. 8 and 9
DPDPE
KD (nM)
NTI
KD (nM)
DPDPE added first 10.0 
 0.4* 0.10 
 0.01†
NTI added first 40.0 
 0.4‡ 0.020 
 0.005§
*No NTI present.
†Obtained in the presence of 80 nM DPDPE.
‡Obtained in the presence of 0.14 nM NTI.
§No DPDPE present.
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etc. In addition, the methods reported here should be readily
adaptable to high-throughput screening, in view of the
minute amounts of receptor and ligand needed for a com-
plete dose-response binding assay and for evaluation of
receptor structural changes.
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